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Cell surface antigens as biomarkers oﬀer tremendous potential for early diagnosis, prognosis, and therapeutic response in a variety
of diseases such as cancers. In this research, a simple, rapid, accurate, inexpensive, and easily available in vitro assay based on
magnetic nanoparticles and magnetic cell separation principle was applied to identify and quantitatively analyze the cell surface
antigen expression in the case of prostate cancer cells. Comparing the capability of the assay with �ow cytometry as a gold standard
method showed similar results.e results showed that the antigen-speci�cmagnetic cell separationwith antibody-coatedmagnetic
nanoparticles has high potential for quantitative cell surface antigen detection and analysis.
1. Introduction
e biomarkers as early warning signs for diseases are
physiological and pathological changes in expression level
or state, which correlate with the progression in a variety of
diseases such as cancers [1, 2]. As the biomarkers show a
disease state very speci�cally and sensitively, they can be used
for the early diagnosis, diﬀerentiation between disease types
with higher accuracy, disease monitoring during and aer
therapy, and as possible therapeutic targets [3–5]. Among the
biomarkers, cell surface antigens play a key role in cellular
functions and pathomechanism of diseases in a variety of
cancers and since many of them are restrictedly produced
against a speci�c tumor, they can act as ideal biomarkers [6].
It is clear that cancer patients would bene�t enormously from
a better availability of such eﬀective molecular indicators that
help in the development of new diagnostic and therapeutic
methods [7, 8].
Although the potential applications of cell surface anti-
gens in cancer diseases appear extraordinarily promising
idea, the greatest potential for using this type of biomarkers
for cancer lies in improving the technology for cancer cells
antigen discovery. So, rapid, simple, accurate, and inexpen-
sive detection methods of the relevant marker are very basic
and important. Currently, a wide range of technologies are
used for detection and characterization of surface antigens;
however, the most widely used method is the analysis of cell
surface antigens by �ow cytometry [9, 10]. Although the �ow
cytometry is the gold standardmethod for accurate and auto-
mated measurements of cell surface antigens, this technique
is not only expensive and only available in specialized centers
but also requires sophisticated equipment and reagents as
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well as highly trained personnel. Furthermore, in resource-
limited countries the access to the technical support and
quality assurance programs for �ow cytometry is oen not
readily available [11, 12].
Recently, a new technique has been developed usingmag-
netic nanoparticles coupled to antibodies, as a non�ow cyto-
metric method, which identi�es cell surface antigen expres-
sion by speci�c antibody-antigen reaction easier, faster, more
eﬃciently, and at lower cost than the other methods [13].
In addition, the use of magnetic nanoparticles as molecular
imaging probes enables noninvasive in vivo studies of antigen
expression of diseases in various internal organs [14, 15].
In this work, a rapid and accurate in vitro assay based
on magnetic nanoparticles and magnetic cell separation
principle was described and developed to discover and
quantitatively analyze the cell surface antigen expression of
Prostate Speci�c Membrane Antigen (PSMA). is assay
relies on the fact that prostate cancer cells overexpress the
PSMA [16, 17].
2. Materials andMethods
2.1.Materials. Sulfo-SMCC cross-linker (Sulfosuccinimidyl-
4-(N-maleimidomethyl) cyclohexane-1-carboxylate), Traut’s
Reagent (2-iminothiolane), and cysteine were purchased
from Sigma Chemical Co. (St. Louis, MO, USA). Nanomag-
D-spio nanoparticles in suspension (diameter: 20 nm, sur-
face: CLD-NH2, 5mg/mL; 2.4mg Fe/mL) were obtained
from micromod Partikeltechnologie GmbH (Rostock, Ger-
many). Midi MACS sorting device, LD, and MS high-
gradient magnetic �eld (HGMF) columns were purchased
from Miltenyi Biotec GmbH (Gladbach, Germany). PD-10
columns were purchased from GE Healthcare (Piscataway,
NJ). e Bradford reagent was purchased from BioRad
(Hercules, CA). Amicon centrifugal �lters (0.5mL capacity,
10 kDa MWCO) were purchased from Millipore (Billerica,
MA).
All other chemicals were supplied by Aldrich and used
as received. J591 monoclonal antibody was obtained from
Professor Neil H. Bander (Cornell University, New York,
USA). Cell culture media and fetal bovine serum (FBS) were
obtained from GIBCO, Invitrogen Corporation (Carlsbad,
CA, USA). Prostate cancer cell lines, DU145 and LNCaP,
were purchased fromnational cell bank of Iran (Pasture Insti-
tute, Tehran, Iran) and Cell Lines Service (CLS, Eppelheim,
Germany).
2.2. Conjugation of J591 Antibody with Nanoparticles. e
monoclonal J591 antibody was thiolated and conjugated
to maleimide functionalized nanomag-D-spio nanoparticles
(Figure 1). erefore, the sulfo-SMCC cross-linker was �rst
added to nanomag-D-spio particles with CLD-NH2 sur-
face to introduce maleimide groups. Speci�cally, 100 𝜇𝜇L of
14.35 𝜇𝜇M Sulfo-SMCC solution in DMSO was added to
5mg of nanoparticles in PBS-EDTA buﬀer under gentle
shaking for 1 h at room temperature. Aer incubation, the
suspension was washed with PBS-EDTA buﬀer with PD-10
size exclusion columns to remove unreacted sulfo-SMCC. In
the next step, primary amines of J591 monoclonal antibodies
were modi�ed with 2-iminothiolane to introduce sul�ydryl
groups. Typically, 8 𝜇𝜇L of 7mM Traut’s reagent solution was
added to 400 𝜇𝜇L of pure antibody solution in PBS-EDTA
buﬀer (1mg/mL) and shaken for 1 h at room temperature.
To remove unconjugated 2-iminothiolane, the solution was
washed three times by 10-kDa cutoﬀ Amicon centrifugal
�lter units with PBS as an eluent.
e antibody conjugation to SPIO nanoparticles was
achieved by addition of the maleimide functionalized parti-
cles to the SH-labeled antibody and incubation under gentle
shaking for 3 h at room temperature. Remaining functional
groups were blocked by addition of 100𝜇𝜇L of 20mM freshly
prepared cysteine solution. Finally, the antibody-labeled
SPIO nanoparticles were puri�ed on magnetic columns
(MACS separator).
2.3. Characterization. e hydrodynamic particle size and
the width of the particle size distribution (polydispersity
index) of nanoparticles were obtained via photon correlation
spectroscopy (PCS) using a Malvern Nano Series ZS particle
size analyzer (Malvern Instruments, Worcestershire, UK).
Samples morphology was observed by transmission electron
microscopy (TEM) on a Tecnai 10 TEM (FEI Company,
USA) operating at 80 k�. To con�rm the feasibility and
sensitivity as magnetic cell separation nanoprobe, magnetic
properties of synthesized nanoprobe were studied by the
use of nuclear magnetic resonance dispersion (NMRD)
pro�les (Spinmaster FFC 2000, STELAR, Italy), in a �eld
strength range extending from 200 𝜇𝜇T to 1.2 T. Additional
measurements of relaxation rate (𝑅𝑅1,2) were performed at 20
and 60MHz on Bruker Minispec system (Bruker, Karlsruhe,
Germany).
e binding of antibodymolecules to SPIO nanoparticles
and the amount of immobilized antibody were determined
by the Bradford assay. Brie�y, 40 𝜇𝜇L of Coomassie Plus
reagent concentrate was added to 160 𝜇𝜇L of dispersion of
nanoparticles, eithermAb-coated or noncoated. Aer 10min
of incubation, the absorbance was measured at 595 nm
using a microplate reader (Stat Fax, Awareness Technologies,
USA). e results were compared to a standard curve of
BSA solution in the concentration range from 10𝜇𝜇g/mL to
150 𝜇𝜇g/mL (Figure 3).
e iron concentrations of the samples were measured
by relaxometry measurements at 20MHz aer digestion of
samples by microwave oven. is was achieved by mineral-
ization of sample in acidic conditions (0.2mL sample, 0.6mL
HNO3, and 0.3mL H2O2) by microwave oven (Milestone
MLS-1200, Sorisole, Italy).emillimolar iron concentration
was determined from the 𝑅𝑅1 relaxation rate of samples, using
following equation [18, 19]:
[Fe] =
󶀢󶀢𝑅𝑅obs1 − 𝑅𝑅
dia
1 󶀲󶀲
𝑟𝑟1 󶀡󶀡s−1 mM−1󶀱󶀱
, (1)
where 𝑅𝑅obs1 is the observed longitudinal proton relaxation
rate,𝑅𝑅dia1 is the relaxation rate of water protons in the absence
of the contrast agent, and 𝑟𝑟1 is the longitudinal relaxivity
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F 1: e Scheme of SPIO nanoparticles Conjugation to J591 antibody, (a) functionalization of SPIO-CLD-NH2 with Sulfo-SMCC, (b)
functionalization of antibody with SH groups using Traut’s reagent, and (c) conjugation of thiolated antibody to maleimide functionalized
SPIO.
de�ned as the relaxation rates induced by 1mmol of iron per
liter of solution. 𝑅𝑅obs1 is the relaxation rate which is measured
on the solution containing the sample; 𝑅𝑅dia1 and 𝑟𝑟1 were
obtained from a standard curve built by measuring the 𝑅𝑅1 of
various dilutions ofmineralized standard sample of iron (ICP
standard, Sigma Aldrich) (Figure 4).
2.4. Cell Culture. LNCaP, a PSMA-expressing (PSMA+), and
DU145, a PSMAnegative (PSMA−) adherent human prostate
cancer cell line, were grown in Dulbecco’s Modi�ed Eagle
Medium supplemented with 2mM L-glutamine, 1% NEAA,
1mM sodium pyruvate, 10% fetal bovine serum, and 1%
penicillin/streptomycin (Gibco, Grand Island, NY, USA). For
DU145, 1.5 g/L sodiumbicarbonate and 0.1mMnonessential
amino acids were used. e cells were cultured in 75 cm2
�as�s, at 37∘C under a humidi�ed 5% CO2 atmosphere. For
subculture and harvesting the cells, they were washed with
PBS followed by treatment with 3mL TrypLE (Gibco, Grand
Island, NY, USA) for 3min to detach the cells. About 10mL
of culture medium was added to neutralize the TrypLE. e
cells were then centrifuged at 3000 RPM for 10min; the
medium was removed and resuspended in complete media
and reseeded into new culture �as�s.
2.5. In Vitro Cytotoxicity. e cytotoxicity of nanomag-
D-spio particles and the corresponding J591-antibody-
conjugated nanoparticles against LNCaP and DU145 cells
was evaluated by using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay (Sigma-Aldrich)
[20]. Exponentially growing LNCaP and DU145 cells were
seeded at a density of 2 × 104 cells/well in 96-well plates
(Cell Star, Germany). e plates were incubated for 24 h
in a humidi�ed incubator with a CO2 concentration of 5%
to allow adherence of the cells. Once adhered, the cells
were incubated with either 0.1mL of medium containing
nanomag-D-spio or SPIO-J591 at iron concentrations rang-
ing from 0.15 to 2.4mM for 2, 8, and 24 h. e culture
medium without any particle was used as the control.
Aer incubation time 10𝜇𝜇L/well (5mg/mL), MTT was
added and incubation was continued for further 3 h.
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F 2: Scheme of the magnetic bead-based cell separation. (a) A
mixture of magnetically labeled and nonlabeled cells is applied on a
separation column. (b) Speci�c cell selection using MACS columns.
Magnetically labeled cells are retained in the magnetic �eld of the
separation column; unlabeled cells pass through the column as
negative fraction. (c)Aer removal of the column from themagnetic
�eld, the desired cells are eluted as the enriched positive fraction.
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F 3: Antibody concentration measurement by Bradford pro-
tein assay.
e medium was carefully removed and the formazan crys-
tals (indicating cell viability) were solubilized by adding
100 𝜇𝜇L DMSO (Sigma-Aldrich) per well. e absorbance
was determined at 570 nm by the Statfax-microplate reader
(Awareness Technology, USA). Experiments were performed
in triplicate and cell survival was determined as a percentage
of viable cells in comparison with control wells. One-way
ANOVA and correlation coeﬃcient between viability and
iron concentration were used to determine whether the SPIO
nanoparticles caused any signi�cant cytotoxicity.
2.6. Fluorescence Microscopy. Fluorescence microscopy was
used to qualitatively analyze the cell surface antigen. LNCaP
and DU145 cell lines were washed with phosphate buﬀered
saline (PBS), detached by TrypLE, and seeded near con-
�uence (2 × 105 cells/well) on 22 × 22mm square glass
coverslips, which were pretreated with plasminogen in 6-
well plates. Aer attachment, the cells were �xed with 4%
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F 4: Calibration curve of iron concentration versus relaxation
rate at 20MHz.
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F 5: Hydrodynamic diameter of nanomag-D-spio (18.65 nm)
and J591-SPIO NPs (24.68 nm).
formaldehyde solution for 15min, washed with PBS, then
treated with Protein-Free Blocking Buﬀer (PFBB, Perbio Sci-
ence, Erembodegem, Belgium) for 1 h at room temperature.
e cells were washed with PBS and incubated successively
with primary J591 anti-PSMA antibody overnight in the dark
at 4∘C. Aer washing with PBS, the cells were incubated
with goat anti-mouse FITC monoclonal antibody for an
additional 1 h at room temperature in the dark. Cells were
then washed, and the slides were mounted using diluted
4′,6-diamidino-2-phenylindole (DAPI) (Vector Labconsult,
Brussels, Belgium) solution for 5min at room temperature
and rinsed once with PBS and once with water. e cover
slips weremounted ontomicroscope slides and observed on a
confocal microscope (LeicaMicrosystems, Groot Bijgaarden,
Belgium). A semiquantitative analysis of the microscope
pictures has been performed by using the ImageJ image
analysis soware (National Institutes of Health).
2.7. Surface Antigen Expression. In a variety of disease,
abnormalities concern not only antigen expression but also
its intensity, which may have diagnostic or prognostic sig-
ni�cance �21, 22]. Quantitative expression of PSMA on
the LNCaP and DU145 cell lines was investigated by �ow
cytometry, as well as by the new proposed method based on
magnetic cell separation.
To detect cell-surface expression of PSMAby �ow cytom-
etry as a gold standardmethod, indirect immuno�uorescence
staining was performed. In brief, cells were trypsynized,
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F 6: TEM images for plain and antibody conjugated SPIO (a) nanomag-D-spio and (b) SPIO-J591, antibody binding causes a signi�cant
reduction of particle agglomeration. e average size of particles estimated from TEM images was about 10–20 nm.
50
45
40
35
30
25
20
15
10
5
0
0.01 0.1 1 10 100
SPIO-C595
Nanomag-D-spio
Proton Larmor frequency (MHZ)
r 1
p
(m
M
−
1
s−
1
)
F 7: NMRD pro�les of nanomag-D-spio and synthesized
nanoprobes.
washed with PBS containing 0.1% fetal bovine serum (FBS),
and 106 cells/tube from each cell line were transferred in
FACS tubes. e cells were resuspended in 90 𝜇𝜇L of washing
buﬀer and were preblocked with FcR Block (human) reagent
(Miltenyi) for 10min at room temperature in the dark. Aer
blocking, primary J591 anti-PSMA antibody (1/150 dilution)
was added to each cell tube (one tube of each cell line
as a control), incubated for 30min in the dark at room
temperature, and then washed 3 × 5min using a washing
buﬀer.
Aer washing, the cells were resuspended and incubated
in goat anti-mouse FITC monoclonal antibody for an addi-
tional 30min at room temperature in the dark. Cells were
then washed, resuspended in 0.5mL of PBS plus 0.1% FBS,
and analyzed immediately using a CyAN-ADP �ow cytome-
ter (Beckman Coulter). All �ow cytometry assessments were
repeated at least three times at weekly intervals for each
sample.
2.8. Magnetic Cell Separation. Immunomagnetic cell selec-
tion as a new method for detection and quantitative expres-
sion analysis of PSMAantigens on prostate cancer cells, based
on magnetic cell separation technique, has been developed
and used (Figure 2).
Human prostate cancer LNCaP cells and DU145 cells
were detached and washed three times with PBS. A approx-
imately 1-2 × 106 cell/tube of each cell type were plated in
15mL tube and incubated with culture medium containing
the synthesized nanoprobe (SPIO-J591) at Fe concentrations
of 2mM.Aer 2 h incubation at room temperature, cells were
washed with PBS three times and resuspended in 1mL PBS
containing 0.1% fetal bovine serum (FBS). e magnetic cell
separation was carried out on a midi MACS system. e
LS separation column was set in the Midi MACS sorting
device, washed twice with 1.0mL of PBS solution. en, the
cell suspension was added to the separation column, washed
three times to obtain the nonmagnetic cells �owing through
the sorting column. Finally, the LS separation column was
removed from the magnetic �eld and eluted the double
positive cells, and then the PSMA+ cells from the MS
separation column. e number of PSMA+ and PSMA− cells
was detected and counted using conventional Trypan blue
staining, under an optical microscope. e percentage of
PSMA expression on the cell surface was determined using
following equation:
e percentage of PSMA expression
=
󶀡󶀡number of PSMA+ cells󶀱󶀱
󶀡󶀡number of PSMA+ cells + number of PSMA− cells󶀱󶀱
× 100.
(2)
3. Results and Discussion
3.1. Synthesis. e J591 monoclonal antibody was thiolated
with Traut’s reagent and conjugated to maleimide func-
tionalized SPIO nanoparticles (Figure 1). e feasibility of
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successfully graing of antibodymolecules to SPIO nanopar-
ticles was con�rmed by the Bradford assay as well as the
measurements of the hydrodynamic size and shape of SPIO
nanoparticles by using PCS and TEM. Analyses by Bradford
protein assay and spectrophotometric readings show the
amount of immobilized antibody of 56 ± 2 𝜇𝜇g Ab/mL of
synthesized nanoprobe (Figure 3). anks to a standard
curve with a commercially available iron standard solution
(ICP standard, Sigma Aldrich), the iron concentration of
particles was estimated to be 43.88 ± 1.2 and 24.22 ± 0.9mM
for nanomag-D-spio and J591-SPIO, respectively, by MR
relaxometry method (Figure 4).
3.2. Characterization. e particle size distribution of SPIO
nanoparticles before and aer antibody conjugation was
determined by PCS (Figure 5). e hydrodynamic parti-
cle diameters are determined to be 18.65 ± 0.21 nm for
nanomag-D-spio and 24.68 ± 0.22 nm for J591-SPIO. Figures
6(a) and 6(b) show TEM images for the spherical-shaped
plain and antibody-conjugated SPIO, respectively. e aver-
age particle size calculated from TEM was 10–20 nm for
nanomag-D-spio and J591-SPIO. e morphology study of
particles from TEM image suggests that antibody molecules
conjugated to SPIO nanoparticle reduce the agglomeration of
nanomag-D-spio particles.
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(b)
F 9: Fluorescent microscopy images (×40 magni�cation) of LNCaP (a) and DU145 (b), prostate cancer cells aer overnight incubation
with primary J591 anti-PSMA antibody and additional 1 h incubated with goat anti-mouse FITC monoclonal antibody. Blue colour: DAPI-
staining of DNA in the nucleus, green colour: goat anti-mouse FITC bonded to primary J591 anti-PSMA antibody.
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F 10: Flow cytometry test shows that DU145 cells lack PSMA expression (a) whereas LNCaP cells express high levels of prostate-speci�c
membrane antigen (PSMA) on their cell surface (b).
NMRD pro�les (Spinmaster FFC2000, STELAR, Italy)
were used to examine the magnetic properties of SPIO and
J591-SPIO nanoparticles under a magnetic �eld strength
between 200 𝜇𝜇T and 1.2 T. e magnetic properties of the
SPIO nanoparticles did not change signi�cantly by being
conjugated to antibody (Figure 7).
𝑅𝑅1 and 𝑅𝑅2 relaxation rate measurements of particles were
performed on a Bruker Minispec operating at 20MHz and
60MHz. A summary of the longitudinal and transversal
relaxivity is provided in Table 1.
3.3. In Vitro Cytotoxicity. Each nanoprobe for medical appli-
cation should show minimal toxicity to the targeted cells.
e in vitro cytotoxic eﬀect of nanomag-D-spio and the
synthesized nanoprobe was assessed using the standard
methyl thiazol tetrazolium bromide (MTT) assay, using
LNCaP and DU145 cell lines. e results aer diﬀerent
incubation times with diﬀerent iron concentrations for both
cell lines show higher than 60% cell viability in relation to
the control sample (Figure 8).e statistical analysis by One-
way analysis of variance (ANOVA), followed by Duncan’s
multiple range test, showed statistically signi�cant evidence
of nonfunctionalized or functionalized SPIO toxicity to cells
(𝑃𝑃 𝑃 𝑃𝑃𝑃2).e𝑃𝑃 value between 2 and 8 h, 2–24 h, and 8–24 h
incubation of DU145 cell line with SPIO-J591 and nanomag-
D-spio was 0.007–0.015, 0.03–0.003, and 0.04–0.36, respec-
tively. In comparison to the LNCaP cell line, these values were
0.17–0.21, 0.15–0.02, and 0.48–0.02. As can be seen, the 𝑃𝑃
values are insigni�cant for most of LNCaP cell line compared
to the DU145 cells.
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T 1: Longitudinal and transversal relaxivities (𝑟𝑟1 and 𝑟𝑟2) of nanomag-D-spio and synthesized nanoprobe at 20 and 60MHz at 37∘C
(Minispec) and the saturation magnetization and size of particles estimated by NMRD pro�les data.
Particle 𝑟𝑟1 (s
−1 mM−1) 𝑟𝑟2 (s−1 mM−1) 𝑟𝑟2/𝑟𝑟1 𝑀𝑀sat (Am2/kg) 𝑟𝑟 (nm)20MHz 60MHz 20MHz 60MHz 20MHz 60MHz
Nanomag-D-spio 21.6 7.6 112 121.8 5.2 16 36.5 8.25
SPIO-J591 14. 9 7.2 83.7 106.5 5.6 14.8 28 8.05
e results of the MTT assay show a moderate negative
correlation (𝑟𝑟 𝑟 𝑟−𝑟𝑟1𝑟𝑟–𝑟−𝑟𝑟71𝑟) between concentration and
viability for most of assays aer 2 h and 8 h incubation, but
aer 24 h incubation a positive correlation (𝑟𝑟 𝑟 𝑟𝑟𝑟𝑟–0.73)
between the concentration and viability was found.
3.4. Cell Surface Antigen Expression. e qualitative and
quantitative expression of PSMA on the LNCaP and DU145
cell lines was investigated by �uorescence microscopy, �ow
cytometry, and proposed method based on magnetic cell
separation.
e qualitative information on the cell surface antigen
expression was obtained by �uorescence microscopy. Figures
9(a) and 9(b) show that the cancer cells were de�ned byDAPI
staining (blue), whilst the green �uorescence represents
PSMA+ cells. e comparison demonstrates considerably
increased �uorescence intensity in the positive LNCaP cells
over the negative DU145 cells.
Flow cytometry analysis was performed to con�rm the
availability and quantitative analysis of desired prostate-
speci�c membrane antigen (PSMA) on cell surface.
Immuno�uorescent staining of LNCaP and DU145 cell
lines showed that LNCaP cells express high levels of PSMA
on their cell surface (95 ± 1𝑟2%), whereas DU145 cells lack
PSMA expression (3 ± 𝑟𝑟2%) (Figure 10). ese results are in
good agreement with previously published studies [19, 23].
Immunomagnetic cell selection was used to determine
the ability of functionalized SPIO for detection and quanti-
tative analysis of desired antigen expression on the prostate
cancer cells surface. Measurements based on magnetic cell
separation method as a proposed immunomagnetic cell
selection showed a 94 ± 3𝑟4% and a 𝑟 ± 𝑟𝑟𝑟% expression of
PSMA on the surface of LNCaP and DU145 cells, respec-
tively. e statistical analysis between the results of antigen
expression by two methods was done using Student’s paired
𝑡𝑡-test. Despite statistical signi�cance (𝑃𝑃 Value of 0.02), the
actual diﬀerence in mean cell surface antigen expression
between the �ow cytometry and magnetic cell separation
method was quite small.
4. Conclusions
An increasing number of surface antigens have been charac-
terized in mammalian cell systems during the past decade.
It has become obvious that these cell surface structures play
an enormous role in early diagnosis, characterization, disease
monitoring during and following therapy, and as possible
therapeutic targets for various illnesses, especially cancers
[24, 25]. However, the diﬃculty and costs of detection,
characterization, and validation of new cell surface antigens
has held back rapid development in this �eld. Hence, the
development of a more eﬃcient and inexpensive detection
methods of the relevant marker is very basic and important.
Here, the detection and quantitative analyses of PSMA on
the prostate cancer cells as an example of a cell surface antigen
were described. e iron oxide nanoparticles with anti-
PSMAmonoclonal antibody (mAb J591) were functionalized
to serve as a PSMA-speci�c molecular probe for in vitro
detection and separation of PSMA+ prostate cancer cell based
on magnetic cell separation technique [26].
Quantitative detection and analysis of desired antigen
expression on the cell surface with proposed method was
carried out and the results were compared with �ow cytom-
etry as a gold standard. Measurements based on the new
immunomagnetic cell selection showed an expression of
PSMA on the surface of LNCaP andDU145 cells by 94±3𝑟4%
and a 𝑟±𝑟𝑟𝑟%, respectively.Whereas using the �ow cytometry
method, the values of 95 ± 1𝑟2% and 3 ± 𝑟𝑟2%, respectively,
have been reported. As the results of both methods are very
similar, the magnetic cell separation for the detection and
quantitative analysis of the cell surface antigen can be a
simple, rapid, accurate, and inexpensive alternative method.
In addition, magnetic separation techniques have several
advantages in comparison with traditional techniques for
biomarker discovery. It is possible to coat nanoparticles with
the ligand of interest, like peptides, aptamers, folic acid, and
so forth and use this method to detect and analyze other
biomarkers, which is not possible by �ow cytometry. Also
molecular imaging enables noninvasive in vivo studies of
biomarkers of diseases in various internal organs by use of
magnetic nanoparticles coupled to targeted reagents [27, 28].
e results obtained from this study prove that use of
antibody-coated magnetic beads for isolation of antigen-
speci�c cells is a convenient and simple method for quantita-
tive cell surface antigen detection and analyses.
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